Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial

Two previous GINECO elderly specific studies in advanced ovarian cancer (AOC) patients highlighted the prognostic value of geriatric covariates for overall survival (OS). This open-label prospective trial was designed to identify the impact of geriatric covariates on OS in AOC patients >= 70 years treated with first-line carboplatin. Geriatric covariates of the 111 patients included median age 79 years (>= 80 years: 41%); performance status (PS) >= 2: 47%; >= 3 major comorbidities: 24%; >= 4 comedications: 68%; activities of daily living (ADL) score < 6: 55%; instrumental activities of daily living (IADL) score < 25: 69%; Hospital Anxiety and Depression Scale (HADS) > 14: 37%. The median OS was 17.4 months. Overall, 74% of patients completed the six planned chemotherapy cycles. Grade 3-4 haematological toxic effects were frequent (50%) but manageable. Grade 3-4 non-haematological toxicities included fatigue (15%), anorexia (12%), infections (9%) and thrombosis (2%). A survival score = exp(0.327*GVS) was developed, where the geriatric vulnerability score (GVS) is the sum of the following (each assigned a value of one): albuminaemia < 35 g/l; ADL score < 6; IADL score < 25; lymphopaenia < 1 G/l; and HADS > 14. With a cut-off >= 3, GVS discriminated two groups with significantly different OS, treatment completion, severe adverse events and unplanned hospital admissions rates. The GVS is a valuable tool for identifying vulnerable patients when treating an elderly AOC population.